Literature DB >> 30100079

Clinical Potential of Estrogen and Progesterone Receptor Imaging.

Hannah M Linden1, Lanell M Peterson2, Amy M Fowler3.   

Abstract

Molecular imaging using 16α-[18F]fluoro-17β-estradiol (FES) and 18F-fluoro-furanyl-norprogesterone PET can assess in vivo function of steroid hormone receptors in breast cancer. These experimental agents have been tested in many single-center clinical trials and show promise to elucidate prognosis and predict endocrine therapy response. The current multicenter trial of FES-PET imaging will help bring this radiotracer closer to clinical use. There is tremendous potential for these tracers to advance drug development, enhance understanding of estrogen receptor-positive tumor biology, and personalize treatment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Estrogen receptor imaging; FES-PET; FFNP-PET; Progesterone receptor imaging

Mesh：

Substances：

Year:  2018        PMID： 30100079      PMCID： PMC6092022          DOI： 10.1016/j.cpet.2018.02.005

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  31 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Authors:  Hannah M Linden; Brenda F Kurland; Lanell M Peterson; Erin K Schubert; Julie R Gralow; Jennifer M Specht; Georgiana K Ellis; Thomas J Lawton; Robert B Livingston; Philip H Petra; Jeanne M Link; Kenneth A Krohn; David A Mankoff
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

3.  Breast cancer adjuvant therapy: time to consider its time-dependent effects.

Authors:  Ismail Jatoi; William F Anderson; Jong-Hyeon Jeong; Carol K Redmond
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

4.  Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.

Authors:  Hannah M Linden; Svetlana A Stekhova; Jeanne M Link; Julie R Gralow; Robert B Livingston; Georgiana K Ellis; Philip H Petra; Lanell M Peterson; Erin K Schubert; Lisa K Dunnwald; Kenneth A Krohn; David A Mankoff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 5.  Assessment of Response to Therapy for Bone Metastases: Is it Still a Challenge in Oncology?

Authors:  J Collignon; C Gennigens; G Jerusalem
Journal:  PET Clin       Date:  2010-08-03

6.  18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Authors:  Yingbing Wang; Karen L Ayres; Debra A Goldman; Maura N Dickler; Aditya Bardia; Ingrid A Mayer; Eric Winer; Jill Fredrickson; Carlos L Arteaga; José Baselga; Henry C Manning; Umar Mahmood; Gary A Ulaner
Journal:  Clin Cancer Res       Date:  2016-12-23       Impact factor: 12.531

Review 7.  Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?

Authors:  D K Woolf; A R Padhani; A Makris
Journal:  Ann Oncol       Date:  2014-12-03       Impact factor: 32.976

8.  Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.

Authors:  Lanell M Peterson; David A Mankoff; Thomas Lawton; Kevin Yagle; Erin K Schubert; Svetlana Stekhova; Allen Gown; Jeanne M Link; Timothy Tewson; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

9.  Combination anastrozole and fulvestrant in metastatic breast cancer.

Authors:  Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Robert B Livingston; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2012-08-02       Impact factor: 91.245

10.  The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer.

Authors:  Qing Qu; Yu Zong; Xiao-chun Fei; Xiao-song Chen; Cheng Xu; Gu-yin Lou; Kun-wei Shen
Journal:  World J Surg Oncol       Date:  2014-04-10       Impact factor: 2.754
View more
  11 in total

1.  18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer.

Authors:  Manoj Kumar; Kelley Salem; Ciara Michel; Justin J Jeffery; Yongjun Yan; Amy M Fowler
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

2.  Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer.

Authors:  Gary A Ulaner; Komal Jhaveri; Sarat Chandarlapaty; Vaios Hatzoglou; Christopher C Riedl; Jason S Lewis; Audrey Mauguen
Journal:  J Nucl Med       Date:  2020-07-17       Impact factor: 10.057

Review 3.  PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.

Authors:  Matthew F Covington; Bhasker R Koppula; Gabriel C Fine; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

Review 4.  Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.

Authors:  Manoj Kumar; Kelley Salem; Amye J Tevaarwerk; Roberta M Strigel; Amy M Fowler
Journal:  J Nucl Med       Date:  2019-11-15       Impact factor: 10.057

5.  PET Imaging of Estrogen Receptors Using 18F-Based Radioligands.

Authors:  Manoj Kumar; Kelley Salem; Justin J Jeffery; Amy M Fowler
Journal:  Methods Mol Biol       Date:  2022

6.  Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader.

Authors:  Laurent Besret; Sébastien d'Heilly; Cathy Aubert; Guillaume Bluet; Florence Gruss-Leleu; Françoise Le-Gall; Anne Caron; Laurent Andrieu; Sylvie Vincent; Maysoun Shomali; Monsif Bouaboula; Carole Voland; Jeffrey Ming; Sébastien Roy; Srinivas Rao; Chantal Carrez; Erwan Jouannot
Journal:  EJNMMI Res       Date:  2020-06-29       Impact factor: 3.138

Review 7.  The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors:  John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2020-02-22       Impact factor: 2.408

Review 8.  Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.

Authors:  Brenda F Kurland; Jay R Wiggins; Amandine Coche; Charlotte Fontan; Yann Bouvet; Peter Webner; Chaitanya Divgi; Hannah M Linden
Journal:  Oncologist       Date:  2020-05-15       Impact factor: 5.837

Review 9.  Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer.

Authors:  Barbara Salvatore; Maria Grazia Caprio; Billy Samuel Hill; Annachiara Sarnella; Giovanni Nicola Roviello; Antonella Zannetti
Journal:  Cancers (Basel)       Date:  2019-10-22       Impact factor: 6.639

Review 10.  Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.

Authors:  Amelie Heesch; Jochen Maurer; Elmar Stickeler; Mohsen Beheshti; Felix M Mottaghy; Agnieszka Morgenroth
Journal:  Cells       Date:  2020-10-21       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.